Skip to content
2000
Volume 11, Issue 2
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955711794519528
2011-02-01
2025-09-05
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955711794519528
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test